528892-33-3Relevant academic research and scientific papers
Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors
Powell, Noel A.,Ciske, Fred L.,Cai, Cuiman,Holsworth, Daniel D.,Mennen, Ken,Van Huis, Chad A.,Jalaie, Mehran,Day, Jacqueline,Mastronardi, Michelle,McConnell, Pat,Mochalkin, Igor,Zhang, Erli,Ryan, Michael J.,Bryant, John,Collard, Wendy,Ferreira, Suzie,Gu, Chungang,Collins, Roxane,Edmunds, Jeremy J.
, p. 5912 - 5949 (2008/03/18)
We report the design and synthesis of a series of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as orally bioavailable small molecule inhibitors of renin. Compounds with a 2-methyl-2-aryl substitution pattern exhibit potent renin inhibition and good pe
FUSED HETEROCYCLIC COMPOUND AND USE THEREOF
-
Page/Page column 226, (2008/06/13)
The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.
BENZOXAZINE AND BENZOXAZINONE SUBSTITUTED TRIAZOLES
-
Page/Page column 18-19, (2010/02/07)
This invention relates to benzoxazine and benzoxazinone substituted triazoles which are inhibitors of the transforming growth factor, ("TGF")-? signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like ki
